Abstract:e23029 Background: With the aging society was coming, more elderly nasopharyngeal carcinoma NPC patients should be pay attention. However, no guideline is proposed for them due to lack of prospective clinical trials. We aimed to use propensity score matching method to evaluate the survival outcome and toxicity of the different treatment modalities for them. Methods: II-IV(UICC 8th) elderly NPC patients (≥65 years) were retrospectively enrolled between 2004 to 2016 in our center. All the patients received definitive IMRT, and were allocated into radiotherapy only (RT), concurrent chemoradiotherapy (CCRT) and neoadjuvant chemotherapy followed with CCRT (NACT). Cisplatin-based chemotherapy was used. Survival outcomes and toxicity were analyzed using propensity score-matching method. Results: There were 142 patients included, and the median age was 68 years. The median follow-up time was 47 months. 23 patients received RT only, 61 patients received CCRT and 58 patients received NACT. After matching for gender, age, T and N stage, chemotherapy and non-chemotherapy patients (22 pairs) were analyzed and shown the chemotherapy group had a better OS (86% vs 68%, p= 0.031). The 3-years LRFS, DMFS and DFS of chemotherapy and non-chemotherapy was 95% and 85% ( p= 0.251), 95% and 86% ( p= 0.307), 86% and 73% ( p= 0.309). Furthermore, 41 pairs who underwent chemotherapy were sub-analyzed according to different modalities. CCRT group showed a comparable 3-years LRFS (100% vs 94%, p= 0.143), DMFS (87% vs 89%, p= 0.608), DFS (81% vs 84%, p= 0.892) and OS (79% vs 66%, p= 0.080) with NACT. For acute toxicity, the incidence of G3-5 bone marrow suppression in non-chemotherapy was significantly lower than chemotherapy group (8.7% vs 36.4%, p= 0.31), and the incidence of G3-5 mucositis was similar ( p= 0.517). Besides that, there was no significant difference in the incidence of G3-5 bone marrow suppression and mucositis between CCRT and NACT group ( p= 0.824, p= 0.618). Conclusions: Chemoradiotherapy could improve the survival rate of the elderly NPC patients compared with radiotherapy only. The acute toxicity of CCRT and NACT was similar and acceptable. CCRT was still the standard treatment modality for them. As for the elderly NPC patients who are in good performance status and comorbidity conditions, NACT might be also worthy of recommendation.

Concurrent Chemoradiotherapy Using Oral Capecitabine and Carboplatin in the Treatment of Elderly Patients with Advanced Nasopharyngeal Carcinoma

Feasibility and Efficacy of Chemoradiotherapy for Elderly Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: Results from a Matched Cohort Analysis

Lobaplatin-based concurrent chemoradiotherapy in elderly nasopharyngeal carcinoma

Concurrent nimotuzumab and intensity‐modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma

Definitive Chemoradiotherapy with Capecitabine and Cisplatin in Elder Patients with Squamous Cell Esophageal Carcinoma

Therapeutic effect of radiotherapy and chemotherapy in 202 elderly patients with nasopharyngeal carcinoma

Feasibility and Efficiency of Concurrent Chemoradiotherapy with Capecitabine and Cisplatin Versus Radiotherapy Alone for Elderly Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: Experience of Two Centers

Matched study comparing induction chemotherapy followed by radiation therapy with radiotherapy alone for advanced nasopharyngeal carcinoma in the elderly

Vinorelbine versus vinorelbine-carboplatin in treatment of elderly patients with advanced non-small cell lung cancer

A matched cohort study of standard chemo-radiotherapy versus radiotherapy alone in elderly nasopharyngeal carcinoma patients

Do Elderly Patients with Locally Advanced Nasopharyngeal Carcinoma Benefit from Radiotherapy Combined with Chemotherapy?

[Phase I Study of Capecitabine with Concurrent Radiotherapy in Early-Stage Nasopharyngeal Carcinoma].

Long-term Results of Elderly Nasopharyngeal Carcinoma Treated with Conventional Radiotherapy Alone in 95 Cases

Concurrent chemoradiotherapy followed by adjuvant chemotherapy for locally advanced nasopharyngeal carcinoma

Radiation Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma in Elderly Patients

Concurrent Chemoradiotherapy versus Intensity-modulated Radiotherapy Alone for Elderly Nasopharyngeal Carcinoma Patients with Pre-treatment Epstein-Barr Virus DNA: A Cohort Study in an Endemic Area with Long-term Follow-up.

Propensity Score Matching Analysis of the Survival Outcome and Toxicity of Different Treatment Modalities for the Elderly Nasopharyngeal Carcinoma Patients.

Clinical Study of Combined Chemotherapy Containing Carboplatin in the Treatment of Aged Patients with Advanced Non-Small Cell Lung Cancer(nsclc)

Induction plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy in elderly patients with locoregionally advanced nasopharyngeal carcinoma

Neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in elderly patients with stage III‐IVa nasopharyngeal carcinoma: A real‐world study based on medical comorbidities